Yes, I'm confused too.
I've read the detailed articles on the Sarepta approval and the FDA definitely pushed the envelope to get it approved. There were only minor signs of improvement, and a surrogate end point definition had to be stretched to get it across the line. Two senior FDA officials recommended the drug application's rejection. It came down a chemical marker, which the fda asserted could indicate a potential benefit.
FDA approves Sareptas Srp901 for the whole population, page-24
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
